Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Total Liabilities (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Total Liabilities for 3 consecutive years, with $890568.0 as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 37.52% to $890568.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $890568.0 through Dec 2025, down 37.52% year-over-year, with the annual reading at $890568.0 for FY2025, 37.52% down from the prior year.
  • Total Liabilities hit $890568.0 in Q4 2025 for Mangoceuticals, up from $804275.0 in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.6 million in Q2 2025 to a low of $240684.0 in Q3 2023.
  • Historically, Total Liabilities has averaged $950249.8 across 3 years, with a median of $1.1 million in 2024.
  • Biggest five-year swings in Total Liabilities: surged 483.15% in 2024 and later tumbled 42.7% in 2025.
  • Year by year, Total Liabilities stood at $276039.0 in 2023, then soared by 416.4% to $1.4 million in 2024, then tumbled by 37.52% to $890568.0 in 2025.
  • Business Quant data shows Total Liabilities for MGRX at $890568.0 in Q4 2025, $804275.0 in Q3 2025, and $1.6 million in Q2 2025.